Novo Nordisk's CagriSema Shows Promising Weight Loss Results with Mild Side Effects
TL;DR Summary
Novo Nordisk's obesity drug CagriSema shows similar safety and efficacy to Eli Lilly's Zepbound, with initial weight loss of around 20% over 68 weeks, but the rate of weight loss plateaus, raising questions about its long-term effectiveness.
- Novo Nordisk’s amylin obesity drug keeps performing like Zepbound STAT
- Data on Novo Nordisk experimental weight-loss drug show mostly mild side effects Reuters
- Novo hunts for ‘maximum potential’ from obesity drug CagriSema Financial Times
- Novo Nordisk Obesity Shot Tied to Greater Weight Loss at Lower Doses Bloomberg.com
- CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in NEJM Yahoo Finance
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
1 min
vs 1 min read
Condensed
79%
177 → 37 words
Want the full story? Read the original article
Read on STAT